Last reviewed · How we verify

Paclitaxel (Pac)

Aravive, Inc. · FDA-approved active Small molecule Under review Quality 0/100

Paclitaxel (Pac) is a Taxane; microtubule stabilizer Small molecule drug developed by Aravive, Inc.. It is currently FDA-approved for Metastatic carcinoma of the ovary, Breast cancer (metastatic and adjuvant), Non-small cell lung cancer. Also known as: Taxol.

Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.

Paclitaxel is an antagonist that targets the transient receptor potential cation channel subfamily V member 1, acting as a vanilloid receptor antagonist. It is used to treat various types of cancer, including non-small cell lung cancer, metastatic pancreatic cancer, stage IV pancreatic cancer, and peritoneal carcinomatosis, often in combination with other treatments such as 5-FU, docetaxel, and enzalutamide.

At a glance

Generic namePaclitaxel (Pac)
Also known asTaxol
SponsorAravive, Inc.
Drug classTaxane; microtubule stabilizer
Targetβ-tubulin / microtubules
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Paclitaxel is a microtubule-stabilizing agent that binds to the β-tubulin subunit of microtubules, preventing their normal dynamic instability. This stabilization disrupts mitotic spindle formation and cell division, leading to G2/M phase arrest and triggering apoptosis in rapidly dividing cancer cells. It is effective across multiple solid tumor types and hematologic malignancies.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Paclitaxel (Pac)

What is Paclitaxel (Pac)?

Paclitaxel (Pac) is a Taxane; microtubule stabilizer drug developed by Aravive, Inc., indicated for Metastatic carcinoma of the ovary, Breast cancer (metastatic and adjuvant), Non-small cell lung cancer.

How does Paclitaxel (Pac) work?

Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.

What is Paclitaxel (Pac) used for?

Paclitaxel (Pac) is indicated for Metastatic carcinoma of the ovary, Breast cancer (metastatic and adjuvant), Non-small cell lung cancer, Kaposi's sarcoma, Gastric adenocarcinoma.

Who makes Paclitaxel (Pac)?

Paclitaxel (Pac) is developed and marketed by Aravive, Inc. (see full Aravive, Inc. pipeline at /company/aravive-inc).

Is Paclitaxel (Pac) also known as anything else?

Paclitaxel (Pac) is also known as Taxol.

What drug class is Paclitaxel (Pac) in?

Paclitaxel (Pac) belongs to the Taxane; microtubule stabilizer class. See all Taxane; microtubule stabilizer drugs at /class/taxane-microtubule-stabilizer.

What development phase is Paclitaxel (Pac) in?

Paclitaxel (Pac) is FDA-approved (marketed).

What are the side effects of Paclitaxel (Pac)?

Common side effects of Paclitaxel (Pac) include Neutropenia, Peripheral neuropathy, Myalgia/arthralgia, Alopecia, Nausea/vomiting, Diarrhea.

What does Paclitaxel (Pac) target?

Paclitaxel (Pac) targets β-tubulin / microtubules and is a Taxane; microtubule stabilizer.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing